BTLA
BTLA is a brake on T and B cells that is pressed by HVEM, a molecule many tumours carry. An antibody that blocks it is being tested with PD-1 blockade in small-cell lung cancer.
Overview
BTLA (chromosome 3q13.2) is an inhibitory receptor on lymphocytes that negatively regulates antigen-receptor signalling through the phosphatases SHP-1 and SHP-2, and can interact with TNFRSF14 (HVEM) in cis on the same cell or in trans on other cells; in cis it appears to restrain trans interactions in naive T cells (UniProt Q7Z6A9). Its partner HVEM binds four distinct ligands, LIGHT, lymphotoxin-alpha, BTLA and CD160, forming a network of stimulatory and inhibitory signals (UniProt Q92956). Tifcemalimab, an anti-BTLA antibody, is in a phase 3 consolidation study with toripalimab in limited-stage small-cell lung cancer (ClinicalTrials.gov NCT06095583).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · BTLA is a brake on T and B cells that is pressed by HVEM, a molecule many tumours carry. An antibody that blocks it is being tested with PD-1 blockade in small-cell lung cancer.
- 1 · What it is
BTLA is a brake on T and B cells that is pressed by HVEM, a molecule many tumours carry. An antibody that blocks it is being tested with PD-1 blockade in small-cell lung cancer.
- 2 · What goes wrong in cancer
An immunoglobulin-superfamily receptor with ITIM motifs; the HVEM interaction is the only established ligand pair.
- 3 · How drugs use it
No product in this corpus aims at BTLA yet. Checkpoint drugs are antibodies that cover one side of an immune ‘stand down’ handshake so T cells stay active.
External identifiers
Sources: HGNC HGNC:21087 (approved symbol, name, aliases and cross-references); UniProt Q7Z6A9 (protein name, function and tissue specificity)
Biology
An immunoglobulin-superfamily receptor with ITIM motifs; the HVEM interaction is the only established ligand pair.
- Lymphocytes (UniProt Q7Z6A9)
- Small-cell lung cancer trials of tifcemalimab with toripalimab (NCT06095583)
Notes
top- Prevalence not recorded: HGNC and UniProt carry no positivity rates.
Latest papers
topQuery for this target: (TITLE:"BTLA" OR ABSTRACT:"BTLA" OR TITLE:"B and T lymphocyte associated" OR ABSTRACT:"B and T lymphocyte associated" OR TITLE:"CD272" OR ABSTRACT:"CD272" OR TITLE:"BTLA1" OR ABSTRACT:"BTLA1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BTLA, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetCD86 (B7-2)
Shares Checkpoint (two meanings), PD-1 / PD-L1 immune checkpoint & T-cell activation and the tag checkpoint-map.
- TargetFGL1
Shares Checkpoint (two meanings), PD-1 / PD-L1 immune checkpoint & T-cell activation and the tag checkpoint-map.
- TargetKIR2DL1 (inhibitory KIR)
Shares Checkpoint (two meanings), Immune checkpoint inhibitors and the tag checkpoint-map.
- TargetPVRIG (CD112R)
Shares Checkpoint (two meanings), Immune checkpoint inhibitors and the tag checkpoint-map.
- TargetCD96
Shares Checkpoint (two meanings), Immune checkpoint inhibitors and the tag checkpoint-map.
- TargetNKG2A (KLRC1)
Shares Checkpoint (two meanings), Immune checkpoint inhibitors and the tag checkpoint-map.
- TargetTDO2
Shares Checkpoint (two meanings) and the tag checkpoint-map.
- TargetCD39 (ENTPD1)
Shares Checkpoint (two meanings) and the tag checkpoint-map.